Latest Conference Articles

Results from the REALIZE study show that combination treatment with telaprevir is superior to standard treatment for patients with hepatitis C virus infection.

High-intensity athletes report more functional gastrointestinal disorders than athletes who engage in lower-intensity sports.

Age is less important than BMI, cardiovascular health, diabetes, and other considerations when evaluating elderly patients for bariatric surgery.

Combination treatment with boceprevir produces a significant reduction in incidence of serious liver complications in patients with hepatitis C.

High consumption carbohydrates, starch, and fructose may increase the risk of developing biliary sludge and stones during pregnancy.

Low vaccination rates among patients with CLD and diabetes have grave public health implications.

Trial indicates that the relationship between body mass index and colonic adenomas is linear, suggesting that obesity can be a risk factor for colonic polyps.

Increased risk of clostridium difficile infection may be associated with exposure to linezolid and clindamycin.

Trial of mindfulness training as an intervention for irritable bowel syndrome (IBS) demonstrates substantial therapeutic impact on bowel symptom severity.

Scheduling, session topics, plenary speakers, and other information for physicians planning to attend DDW 2011.

Review of existing guidelines for cardiovascular disease and diabetes shows a continuing reliance on experience and expert opinion.

Enhancing beta cell regeneration and modulating autoimmune destruction of beta cells may be the key to effective diabetes treatment.

Use a combination of recommendations and clinical judgment to determine the proper calcium and vitamin D requirements for each patient.

Clinical trial results used to support the current recommendations for target blood pressure don't tell the whole story.

Presentation at AACE 2011 focuses on understanding environmental toxins and other disrupters to the endocrine system.

George Bakris, MD, discusses combination therapies for treating hypertension, chronic kidney disease, and diabetes.

Eric Topol, MD, discusses pharmacogenetics, molecular medicine, genomics, and the future of diabetes treatment.

Daniel Von Hoff, MD, discussed novel treatments for rare cancers at the AACE annual meeting.

Study finds no improvement in cognitive impairment among patients with multiple sclerosis treated with ginkgo biloba extract.

Slow-release formulation of zinc is safe for Alzheimer's disease patients, and effectively raises serum zinc levels, but does not benefit cognition.

Safinamide improves "on time" and other symptoms and reduces dyskinesias in patients with Parkinson's disease.

Study results show that oral laquinimod reduces the annual relapse rate in patients with relapsing-remitting multiple sclerosis.

More than half of patients with type 2 diabetes have experienced hypoglycemia, with many reporting experiences during activities such as driving and working.

Research shows promising results for PPAR modulators, long-acting GLP-1 receptor agonists, SGLT2 inhibitors, and other new classes of diabetes treatments.

Poorly designed trials evaluating hormonal control in critically ill patients may lead to erroneous conclusions with serious consequences for patients.

Molecular medicine is the future of cancer treatment, but also has many potential applications in endocrinology.

Patients treated with Qutenza reported significant relief from pain associated with PHN, regardless of gender, age, PHN duration, or baseline pain score.

Selegiline inhibits MAO-A in the brain of patients with Parkinson's Disease without elevating the risk of hypertensive crisis from dietary tyramine.

Results from the CLARITY study show cladribine reduces the relapse rate in multiple sclerosis patients who have failed other disease-modifying therapies.

Amantadine promotes rapid functional recovery in patients with disorders of consciousness after traumatic brain injury.